ZYBERNO
Stock Report
Updated Jun 6, 2026

FutureTech II Acquisition Corp. (FTII)

Healthcare • Over The Counter

$12.02

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
0.0/100
POOR BUSINESS
FutureTech II Acquisition Corp. (FTII) scores 0/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-7.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

FutureTech II Acquisition Corp. (FTII) stock report — Zyberno Score 0/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:12.02
Market Cap:$3.01M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.79M
B. Profitability Assessment

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Growth (Linear) (1)

Net Income Growth Rate (Linear):-36.4%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.21x
Quick Ratio:0.21x
Cash Ratio:0.02x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-4.72x
Times Interest Earned:-4.72

Capital Structure (4)

Working Capital:-5,484,501.00
Cash And Cash Equivalents:160,723.00
Long Term Debt:$0.00
Net Debt:$781.80K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00
Operating income TTM: -$1.02M
Linear Growth: -50.0%
📊 Click to view full FTII Operating Income analysis & methodology →

Bottom Line Performance (3)

Net income TTM: -$1.20M
Linear Growth: -36.4%
📊 Click to view full FTII Net Income analysis & methodology →
Income Before Tax:-$1.02M
Ebitda Ttm:-1,016,239.00

Operating Expenses (5)

Operating Expenses:1,811,606.00
R And D Expense:0.00
Sga Expense:1,491,606.00
Income Tax Expense:$186.15K
Interest Expense:100,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$10.58M
Current Assets:$1.45M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:20,163,888.00
Current Liabilities:6,930,789.00
Long Term Debt:$0.00
Short Term Debt:$942.52K

Equity & Capital (3)

Equity:-$9.58M
Retained Earnings:-$9.58M
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:942,520.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$2.10M$0.00

Investment Activities (1)

Investing Cash Flow:$17.63M

Financing Activities (3)

Financing Cash Flow:-$17.10M
Dividends Paid Ttm:0.00
Stock Repurchase:17,400,674.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$4.81

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$7.70

Book Value & Capital (2)

Book Value Per Share:-$38.33
Cash Per Share:0.64

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:10.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Net Income Growth Rate (Linear):-36.4%
Operating Income Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:FTII
Company Name:FutureTech II Acquisition Corp.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:Over The Counter
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:250.00K
Shares Outstanding Basic:250.00K
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-06 12:10:09 UTC
Data Timestamp:2026-06-06T12:10:09.624835
Scroll to Top